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Calcium antagonists have been used for the treatment of
cardiovascular disorders for more than a quarter of a century.
Until very recently, physicians were under the impression that
these drugs were efficient, well tolerated and safe. Over the
past 3 years, calcium antagonists have been accused of increas-
ing the risk of heart attacks, arrhythmias, strokes, gastrointes-
tinal and intraoperative bleeding, Parkinson’s disease, systemic
lupus, acquired immune deficiency syndrome (AIDS), malig-
nancies, cognitive dysfunction and suicide. The sheer multi-
tude and heterogeneity of these accusations are puzzling.
Perhaps even more puzzling is the fact that most papers
bringing these adverse events to our attention stem from the
pen of the same few investigators. Most puzzling, however, is
the unparalleled new media coverage that accompanied these
retrospective studies, causing much unnecessary anxiety and
even panic among our patients.
Cardiovascular disorders, such as hypertension, hyperlipid-
emia and arrhythmias, commonly require treatment for years
and even decades. Because morbidity and mortality of these
disorders (particularly when mild) are relatively low, the
benefits from treatment are comparatively small. Thus, the
British Medical Research Council (MRC) study (1) allows us
to calculate that almost 1,000 patients need to be exposed to
antihypertensive therapy with a diuretic drug for 1 year to
prevent one single stroke. Diuretic drugs are comparatively
powerful drugs to prevent stroke, and benefits are easy to
demonstrate. In contrast, the effects of beta-adrenergic block-
ing agents on strokes, and the benefits of beta-blockers and
diuretic drugs on coronary artery disease, are considerably
smaller. This means that numerous patients will be exposed to
the adverse effects and cost of these drugs without ever
harvesting any real benefit. Given this scenario of small
benefits and longtime exposure, any potential risk of malig-
nancy associated with drugs to treat chronic cardiovascular
disorders has to be taken very seriously.
Chemical agents can increase the risk for malignancy either
by being directly carcinogenic or by impeding the immunore-
sponse or apoptosis, or both. Direct carcinogenicity usually
requires many years and even decades of exposure and is
specific for certain malignancies only. In contrast, the effects of
immunosuppression or inhibition of apoptosis can manifest
themselves within a much shorter time frame and affect a much
larger spectrum of malignancies. It is this latter mechanism
(apoptosis) that is purported to be affected by calcium antag-
onists. In this regard, the report of Braun et al. (2) in the
current issue of the Journal provides some reassurance. In a
cohort of .11,000 patients, half of whom were receiving a
calcium antagonist, no increase in malignancy was observed.
Of note, most patients were receiving the short-acting forms of
nifedipine, diltiazem and verapamil—the very same drugs that
in much smaller studies were accused of carcinogenicity.
Several other studies from powerful data bases also have
refused the hypothesis of calcium antagonists increasing the
risk of malignancies. Thus, in .4,000 patients of the West of
Scotland Cancer Surveillance Unit (3), a retrospective analysis
showed no increased malignancy risk. Similarly, a Danish
cohort study (4) of .17,000 patients showed no excessive
malignancy risk in those taking a calcium antagonist. In all four
prospective, randomized trials assessing morbidity and mortal-
ity, the malignancy risk was lower in patients receiving calcium
antagonists than in those receiving either placebo or diuretic
drugs (Fig. 1) (5–8). Perhaps the most powerful set of data
providing evidence against the possibility of calcium antago-
nists meddling with apoptosis stems from the Mayo Clinic. In
621 posttransplant patients with immunosuppression by cyclo-
sporin, Textor et al. (9) found that there was no excess
malignancy risk in those receiving calcium antagonists (despite
comparable immunosuppression) compared with those who
were not.
Do the data of Braun et al. (2) and other similar studies
allow us to firmly refute the possibility that calcium antagonists
are carcinogenic? Certainly not. Low grade direct carcinoge-
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Figure 1. Prospective studies reporting malignancy rates in calcium
antagonists users. CA 5 calcium antagonists; CI 5 confidence interval;
HCTZ 5 hydrochlorothiazide; Nifedipine SR 5 nifedipine slow
release; SYST-EUR 5 Systolic Hypertension in Europe (Staessen et
al. [5]); MIDAS 5 Multicenter Isradipine Diuretic Atherosclerosis
Study (Borhani et al. [6]); PRAISE 5 Prospective Randomized
Amlodipine Survival Evaluation (Packer et al. [7]); STONE 5 Shang-
hai Trial of Nifedipine in the Elderly (Gong et al. [8]).
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nicity may take decades to surface and cannot be ruled out by
short-term (up to 5 years) trials however thoroughly they were
designed. By the same token, the available data do not allow us
to rule out that other drugs used to treat cardiovascular
disorders, such as angiotensin-converting enzyme inhibitors,
beta-blockers, antiarrhythmic agents or lipid-lowering or di-
uretic drugs, would not ultimately turn out to be low grade
carcinogens. However, the above data set makes it extremely
unlikely that calcium antagonists increase the risk of malig-
nancy by affecting apoptosis or immunosuppression, or both.
Thus, although we can be reassured to a great extent by
existing data, we will have to continue to be vigilant with regard
to carcinogenicity of all drugs that are used to treat cardiovas-
cular disorders for years and decades.
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